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Abstract
Background: The problem of prostate cancer progression to androgen independence has been extensively studied. Several
studies systematically analyzed gene expression profiles in the context of biological networks and pathways, uncovering
novel aspects of prostate cancer. Despite significant research efforts, the mechanisms underlying tumor progression are
poorly understood. We applied a novel approach to reconstruct system-wide molecular events following stimulation of
LNCaP prostate cancer cells with synthetic androgen and to identify potential mechanisms of androgen-independent
progression of prostate cancer.
Methodology/Principal Findings: We have performed concurrent measurements of gene expression and protein levels
following the treatment using microarrays and iTRAQ proteomics. Sets of up-regulated genes and proteins were analyzed
using our novel concept of ‘‘topological significance’’. This method combines high-throughput molecular data with the
global network of protein interactions to identify nodes which occupy significant network positions with respect to
differentially expressed genes or proteins. Our analysis identified the network of growth factor regulation of cell cycle as the
main response module for androgen treatment in LNCap cells. We show that the majority of signaling nodes in this network
occupy significant positions with respect to the observed gene expression and proteomic profiles elicited by androgen
stimulus. Our results further indicate that growth factor signaling probably represents a ‘‘second phase’’ response, not
directly dependent on the initial androgen stimulus.
Conclusions/Significance: We conclude that in prostate cancer cells the proliferative signals are likely to be transmitted
from multiple growth factor receptors by a multitude of signaling pathways converging on several key regulators of cell
proliferation such as c-Myc, Cyclin D and CREB1. Moreover, these pathways are not isolated but constitute an
interconnected network module containing many alternative routes from inputs to outputs. If the whole network is
involved, a precisely formulated combination therapy may be required to fight the tumor growth effectively.
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Introduction
Prostate cancer is one of the most commonly diagnosed cancers
and the second leading cause of cancer-related death in North
American men [1]. While androgen withdrawal therapy is often
effective initially, most cases progress to the much more aggressive
androgen-independent phenotype. Despite significant research
efforts, the mechanisms underlying tumor progression are poorly
understood. Roles for several signaling pathways have been
established, but not a systemic picture. For example, IGF signaling
has been implicated in the progression from androgen-dependent to
androgen-independent states [2], but also has been shown to suppress
AR trans-activation via FoxO1 and thus have inhibitory effects on the
growth of prostate cancer cells[3], EGFwas reported to mimic effects
of androgen on the gene expression and independently stimulate
growth of androgen-dependent prostate cancer cells [4]. Other
studies have produced evidence of interplay between androgen
signaling and TGF-beta [5],[6], FGF [7],[8] and VEGF [9].
Most of the research cited above has been hypothesis-driven
rather than data-driven. Hypothesis formulation is susceptible to
bias due to investigators’ preferences and current research trends
about what is perceived as ‘‘interesting’’. A complementary data-
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advanced data analysis algorithms could enhance understanding of
the many cellular processes that underlie progression of prostate
cancer to the androgen-independent stage and could pave the way
to new therapies and to achieve greater efficacy from better
directed use of existing therapies.
Genome-wide expression profiling haven been widely
applied to complex diseases, including prostate cancer
[4],[10],[11],[12],[13],[14]. Several recent studies also systemat-
ically analyzed gene expression profiles in the context of biological
networks and pathways, uncovering novel aspects of prostate
cancer [15],[16],[17]. Despite this progress, truly systemic analysis
which would take into account both gene expression and
proteomic data from the same sample remains an elusive goal.
A critical challenge is to perform robust integrated analysis of the
datasets produced by so different molecular platforms. This is a
hard informatics problem because microarray and proteomics
data could not, in most cases, be directly compared to each other.
For example, studies in yeast have shown that correlation between
levels of mRNA and corresponding proteins were insufficient to
make reliable predictions about protein levels from gene
expression data [18]. A recent study of prostate cancer specimens
showed concordance between proteomic and genomic data
ranging from 46% to 68% based on the ‘‘absent/present’’ calls;
however, correlations were low when actual levels of expression
were compared [19]. As shown in a recent work [20], much more
extensive quantitative protein characterization leads to significant
improvement in correlation between levels of protein and gene
expression. Still, there are multiple intrinsic sources of the
discordance, including mRNA degradation, alternative splicing,
translational regulation, post-translational modifications, and
protein degradation [21]. These cannot be overcome by
technology improvements alone and have to be addressed by
new analytical approaches to data integration. Earlier efforts in
this area utilized pre-defined sets of genes (pathways, Gene
Ontology categories) to look for concordance between proteomic
and genomic data on this level [22],[23].
Recently we have developed a new computational methodology
which may help to advance integrated analysis of multiple types of
data one step further [24]. Our approach combines disease- or
condition-specific, high-throughput molecular data with the global
network of protein interactions to identify nodes which occupy
significant network positions with respect to differentially
expressed genes or proteins in the presented molecular datasets.
Even when there is significant noise and discordance in the data
itself, predictions of the algorithm are likely to converge on a
common set of signaling proteins in the pathways responsible for
changes in the expression of target genes and proteins. Often the
activity of such signaling proteins is modified by subtle post-
translational modifications, binding to second messengers, or
recruitment to a particular sub-cellular locale. These events are
not explicitly reflected in corresponding molecular profiles; thus,
they remain ‘‘hidden’’ from the standard molecular assays. Our
methodology is able to find many such ‘‘hidden’’ proteins by
identifying sets of their likely downstream targets and assessing
enrichment of such sets by differentially expressed genes or
proteins. We call this procedure ‘‘topological scoring’’ (refer to
‘‘Methods’’ section for more details).
In our earlier work this method was tested on a set of microarray
gene expression data from psoriatic patients where it was able to
correctly identify many key regulatory proteins whose relation to the
disease is confirmed by independent studies [24]. In the present study
we have applied the topological scoring approach to investigate the
response of LNCap prostate cancer cells to treatment with synthetic
androgen (R1881), as a well-studied model system for prostate cancer
progression. We took a data-driven approach, without having any
preconceived hypothesis regarding cellular processes activated by
androgen in these cells. We have collected and analyzed both gene
expression and proteomic data in order to cross-validate predictions
based on different types of data and evaluate the utility of this
approach to integrative data analysis.
Results
Genes and proteins affected by androgen treatment
identified by microarray and protein mass-spectrometry
In order to interrogate the role of androgen in prostate cancer,
the androgen-responsive prostate cancer cell line LNCaP was
treated with synthetic androgen R1881 (see ‘‘Methods’’ section for
details). LNCaP cells treated with androgen showed increased cell
proliferation whereas the control cells stopped growing in the
androgen depleted medium. Using statistical analysis of gene
expression data we have identified 347 and 257 genes that were
up- and down-regulated, respectively, in treated vs. untreated cells
(FDR#1%) (Table S1). The up-regulated genes included known
androgen-induced genes such as Kallikrein 3 (KLK3; a.k.a. PSA),
FK506 binding protein 5 (FKBP5), N-myc downstream regulated
1 (NDRG1) and fatty acid synthase (FASN). Using iTRAQ 2DLC-
MS/MS-based proteomic profiling of androgen-treated vs.
untreated LNCap cells, we have identified 70 and 39 proteins
that were elevated or down-regulated, respectively, in treated cells
compared to untreated cells (Table S1) (Details of the mass
spectrometry and statistical analyses are described in [25]). The
androgen-regulated protein data set included gene products for the
known up-regulated genes mentioned above, as well as several
other proteins previously known and unknown to be regulated by
androgen. Sets of up-regulated genes and proteins have 13
common members which is ,17% of the smaller set. For down-
regulated genes and proteins the level of concordance is ,8%.
Topologically significant nodes in the global signaling
network
In order to investigate putative signaling mechanisms which
activate gene and protein expression after androgen stimulation, we
have applied our recently developed technique of topological
significance analysis [24]. We submitted the lists of up-regulated
genes and proteins to the on-line version of our topological
scoring tool (http://topology.genego.com/zcgi/topology_scoring.
cgi) to identify key regulatory proteins whose activity in treated cells
might have accounted for changes in gene and protein levels. Gene
expression and proteomic data were submitted to the scoring
procedure separately, resulting in two sets of topologically significant
regulatory proteins. Each node in the global network of protein
interactionswasassignedtopologicalscores(topologicalp-values)with
respect to each set of molecular data. To control the false discovery
rate (FDR) the significance level filter was applied. Using FDR#5%
we identified 962 topologically significant proteins from gene
expression data and 577 topologically significant proteins from
proteomic data (Table S2). Interestingly, the two sets of topologically
significant proteins contain 301 common elements (or 52% of the
smaller set).This result is in stark contrast with only 17% overlap
between lists of up-regulated genes and up-regulated proteins.
Growth factor signaling network is highly implicated in
androgen response
For functional analysis, both sets of the topologically significant
proteins were loaded into the MetaCore
TM software package
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functional processes as defined by ‘‘GeneGo process networks’’.
We used all proteins in the MetaCore network (‘‘default’’ setting)
as the reference list for calculating enrichment p-values. As would
be expected, the top-scoring process is ‘‘Androgen receptor
nuclear signaling’’ (Figure 1a). Surprisingly, however, this process
is highly enriched only in proteins whose topological scores are
derived from the gene expression profile; 82 of 126 nodes in this
process network are deemed significant with respect to over-
expressed genes. In contrast, only 19 nodes are deemed significant
with respect to up-regulated proteins from the iTRAQ dataset.
The next highly enriched process network is ‘‘Growth factor
regulation of cell cycle’’. Unlike androgen signaling, this network is
highly enriched in proteins that are topologically significant for
both gene expression and proteomic data. Of 186 nodes in this
network, 95 are highly scored with respect to over-expressed genes
while 63 are highly scored with respect to iTRAQ-identified
proteins up-regulated after androgen treatment. In combination,
49 nodes are confirmed as topologically significant from both sets
of molecular data. Close examination of this process reveals that
topologically significant proteins are present on all levels of
signaling hierarchy, including several Growth factors (EGF, FGF,
VEGF-A), receptors (IGFR, EGFR, ActRIIB, VEGFR-2), signal-
ing kinases (AKT, GSK3, PI3K, JNK, ERK1/2, PKC),
Figure 1. Functional analysis of topologically significant proteins. (A) Enrichment of GeneGo process networks by topologically
significant proteins identified using all up-regulated genes and proteins. (B) Enrichment of GeneGo process networks by topologically significant
proteins identified using truncated sets of data (excluding genes and proteins directly regulated by androgen receptor). Orange bars–
enrichment by significant proteins identified using proteomics data set. Blue bars–enrichment by significant proteins identified using gene
expression data.
doi:10.1371/journal.pone.0010936.g001
Networks in Prostate Cancer
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STAT1, STAT3) and, finally, cyclin kinases (Cyclin D, Cyclin E)
that directly regulate cell cycle (Figure 2). Importantly, topological
significance of many of these proteins was confirmed for both
datasets. For comparison we have also performed pathway
enrichment analysis of the original sets of up-regulated genes
and proteins. Interestingly, the majority of identified pathway
maps for both gene expression and proteomics sets are related to
metabolic processes, most of them to fatty acid metabolism (Table
S3). Additionally, several signaling pathways are revealed by this
analysis, notably Growth factor signaling via MAPK and PIK3,
regulation of lipid metabolism and one pathway map related to
cell cycle. However, none of the signaling pathways is very highly
ranked and overall significance of the enrichment is low compared
to the results obtained for proteins identified by topological
scoring. Enrichment of GeneGo networks by up-regulated
proteins does reveal Androgen signaling network, but it is also at
the bottom of the list (p=0.007). Except for the insulin signaling
there seem to be no consistency between networks enriched in up-
regulated genes and up-regulated proteins. Overall it appears that
functional analysis of differentially expressed genes and proteins
tends to identify core target pathways, such as metabolism, while
the anaylysis of topologically significant proteins reveals key
signaling processed activated in androgen-stimulated cells.
In order to investigate whether significant differences in sizes of
the sets used in our analysis could have affected the results we
randomly sampled the pool of genes and proteins and added them
to the differentially expressed sets. This step was followed by
enrichment analysis of the extended sets. However, the results
show that no new maps or networks become significant for larger
sets and moreover, significance of previously identified maps and
networks steadily declines as more random genes are added. (See
Table S4).
Delineating androgen-dependent and androgen-
independent activity
The results presented above suggest that a majority of proteins
in the signaling network connecting multiple growth factors to
regulation of cell cycle may become active after androgen
stimulation. The resulting activation of cell proliferation could
become a key contributing mechanism for the switch to androgen
independence in prostate cancer. To further verify this conjecture
we need to investigate whether or not this result depends on the
direct activity of androgen receptor. Thus, our next step was to
delineate signaling effects that are independent of direct activation
of androgen receptor.
First, we used MetaCore
TM to identify which of the over-
expressed genes and up-regulated proteins are direct targets of
transcriptional regulation by androgen receptor. To this end we
built the ‘‘nearest neighbors’’ network around androgen receptor
with the interaction filter in MetaCore set to allow only
‘‘transcriptional regulation’’ type of links. Lists of up-regulated
genes and proteins were mapped onto the resulting network. Using
this network we further selected nodes that are both: ‘‘down-
stream’’ of androgen receptor and have experimental data
associated with them. We found 45 direct targets of androgen
Figure 2. Growth factor regulation of the G1-S transition in cell cycle. Red dots indicate proteins identified as topologically significant using
the gene expression profile. Blue dots indicate proteins identified as topologically significant using the proteomics profile. Red boxes–proteins
identified as topologically significant from both sets of data.
doi:10.1371/journal.pone.0010936.g002
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of up-regulated proteins. These molecules were excluded from the
original lists and truncated sets were re-analyzed with the
topological significance tool with subsequent functional analysis
of topologically scored nodes in MetaCore
TM. We identified 565
significant proteins on the basis of iTRAQ data and 668 significant
proteins on the basis of gene expression dataset (with FDR,5%,
Table S5). One observation immediately noticeable from the
examination of the enrichment diagram is the absence of the
androgen signaling network (Figure 1b). This absence confirms
that many proteins in the androgen pathway received high
topological scores on the strength of over-expression of a large
number of direct targets of androgen receptor. Once these targets
are eliminated from consideration, scores for proteins in the
androgen-regulated pathway dropped below significance level. In
contrast, high enrichment for the network of growth factor
regulation of cell cycle remained virtually intact. While number of
nodes on this network scored on the basis of microarray data
decreased from 95 to 78, the number of nodes scored based on
iTRAQ data increased from 63 to 71. The overlap between the
two sets of significant proteins also increased to 54 (or 76% of the
smaller set). This finding supports the suggestion that activity of
this pathway is independent of direct androgen action and may
represent important mechanisms for the switch to androgen-
independent proliferation in prostate cancer.
Top-ranked regulatory proteins and their pathways
Next we examined the top-ranked molecules in the sets of
topologically scored proteins. Our goal was to determine specific
transcription factors which drive gene expression response after
androgen treatment and identify regulatory cascades that activate
them. There are several transcription factors that can regulate
expression of significant numbers of ‘‘targets’’ among over-
expressed genes or up-regulated proteins or both (Table 1). For
example c-Myc has 25 targets among 70 up-regulated proteins
identified by iTRAQ and 63 targets among 347 over-expressed
genes identified by microarray analysis. c-Myc is ranked #1i n
topological scoring based on iTRAQ data and #11 in the scoring
based on gene expression (still in the top 2%). Other transcription
factors that received high topological scores with respect to both
datasets are SREBP1 and YY1, which are important regulators of
enzymes involved in lipid and fatty acids metabolism. In contrast,
CREB1 and ATF-4 are the top-scoring transcriptional regulators
with respect to microarray data but they do not receive any score
based on the iTRAQ data. The reason for such discrepancy is lack
of significant number of CREB1 and ATF-4 targets among up-
regulated proteins identified by mass-spectrometry (Table 1). This
may indicate activity of some posttranscriptional processes
blocking synthesis or inducing degradation of these proteins at
the time of sampling. While transcription factors often receive high
topological scoring due to the significant number of their direct
targets in the experimental datasets, the upstream signaling
molecules are scored based on the enrichment of sets of their
‘‘remote targets’’–genes and proteins a few steps downstream on
signaling pathways.
Examination of individual signaling cascades leading to the top
transcriptional regulators reveals that PI3K signaling is supported
by consistently high topological scores derived from both
proteomics and microarray datasets. Figure 3 shows this cascade
in the context of IGF signaling. The PI3K cascade is highlighted
by the red line, while all of its elements that achieve high
topological scores with respect to both sets are marked by red
boxes. Such consistent scoring suggests the central role of this
pathway in regulating events that follow androgen treatment. Most
likely, its role in this system is inhibition of GSK3 kinase and its
ability to phosphorylate c-Myc and cyclin D (Fig. 3). Normally
such phosphorylation would target these molecules for proteolysis,
thus limiting cell proliferation. In this situation, however, c-Myc
appears to be persistently activated judging by the high number of
its direct targets present in both sets. One likely reason for the
persistent activity of PI3K signaling is homozygous mutation of
PTEN in LNCaP cells leading to the lack of its expression in this
system [26]. This effect may be exacerbated by the combination of
high level of Kallikrein 3, over-expression of IGF receptor, and
under-expression of IGF-binding proteins (IBPs). Kallikrein 3 (also
known as PSA) is highly up-regulated in prostate cancer and is
consistently over-expressed on both mRNA and protein levels in
our experimental data. It was previously shown that PSA has
proteolytic potential with respect to IGF-binding proteins
[27],[28]. Moreover, it was suggested that this might be a
mechanism by which bioavailability of IGF is increased,
contributing to the growth of prostate cancer cells [29],[30].
In our analysis we have obtained several additional pieces of
evidence to support this hypothesis. First, IGF-binding proteins
received high topological scores based on both microarray and
iTRAQ data. This result confirms that they are highly relevant to
observed changes in gene and protein expression following
androgen treatment of LNCap cells. Second, upon androgen
treatment we found that expression levels of at least one of the
IGF-binding proteins (IBP3) and of IGF receptor shift in opposite
Table 1. Scoring of transcriptional regulators with significant number of direct targets among up-regulated genes and proteins.
Transcription factor iTRAQ data set Affymetrix dataset
# of direct
targets in dataset Scoring percentile
# of direct targets
in dataset Scoring percentile
c-Myc 25 99.9 63 98.6
ATF4 0 Un-scored 10 99.6
CREB1 2 Un-scored 37 99.8
P53 5 Un-scored 37 Un-scored
SREBP1 8 78.0 14 99.3
SP1 15 Un-scored 64 Un-scored
Ikaros 4 93.0 2 Un-scored
YY1 6 95.8 7 90.0
doi:10.1371/journal.pone.0010936.t001
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IGF-receptor is 46% over-expressed. Down-regulation of IBP3 on
the genomic level in addition to proteolytic activity of PSA would
contribute to lower concentration of IBP3 protein and increased
availability of IGF. The resulting higher level of IGF is matched by
over-expression of its receptor, leading to high activity of
downstream pathways.
Discussion
Growth factor network as the main response module to
androgen stimulation in LNCap cells
Our topological analysis identified the network of growth factor
regulation of cell cycle as the main response module for androgen
treatment in LNCap cells. As described in the introduction,
different aspects of growth factor signaling have been extensively
investigated in the context of the prostate cancer switch to
androgen-independent mode. Our results support these earlier
observations from a complementary systems-level, data-driven
perspective. Instead of focusing on activity of individual proteins,
we show that the majority of signaling nodes in the network
connecting multiple growth factors to key regulators of cell cycle
occupy significant positions with respect to the observed gene
expression and proteomic profiles elicited by androgen stimulus.
This network contains multiple conventional ‘‘pathways’’ trans-
mitting signals from growth factor receptors. These include
signaling via MAP kinases, PI3K pathway and signaling via
SMADs and cross-talk among these systems. Thus it is reasonable
to conclude that in prostate cancer cells the proliferative signals are
transmitted from growth factor receptors by a multitude of
signaling pathways converging on several key regulators of cell
proliferation such as c-Myc, Cyclin D and CREB1. Moreover,
these pathways are not isolated but constitute an interconnected
network module containing many alternative routes from inputs to
outputs.
Our results further indicate that growth factor signaling
probably represents a ‘‘second phase’’ cell response to androgen
stimulus. When all direct targets of androgen receptor are
removed from consideration, most proteins in the growth factor
network are still highly scored with respect to the remaining sets of
Figure 3. Map for IGF signaling showing topologically significant genes identified from using ‘‘truncated’’ sets of Affymetrix and
iTRAQ data. Red level in the ‘‘thermometers’’ represents relative rank (percentile) of a protein in the corresponding list of topologically significant
proteins. The number identifies the dataset from which significance was calculated: 1-iTRAQ, 2-Affymetrix. Red boxes and highlighted path illustrate
signaling cascade with strongest support from both sets.
doi:10.1371/journal.pone.0010936.g003
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mediated by combined effects of high levels of PSA and growth
factor receptors and low levels of growth factor inhibitors, such as
IGF-binding proteins (IBPs) (Fig. 3). Proteolytic action of PSA may
further contribute to the lowering of IBPs levels. At the same time,
PSA expression can be sustained independently of androgen
receptor by CREB1 and some other transcription factors [31].
When these factors are activated via growth factor signaling
pathways, a positive feedback loop arises that can sustain high
levels of PSA and cell proliferation even in the absence of activated
androgen receptor. We have noted that CREB1 is ranked #1i n
topological scoring of gene expression data, implying that it is
highly active in this system.
Although further experimental work, such as siRNA studies is
needed to confirmthese inferences, ifproved correct they may lead us
to reconsider our approach to finding targeted therapies for prostate
cancer. Biological networks are robust in a sense that there are many
alternative ways to transmit a molecular signal from one point to
a n o t h e r .G i v e nh i g hm u t a t i o nr a t e so fg e n e si nc a n c e rc e l l s ,i ti sl i k e l y
that, even ifwe block a certain cascade with a targeted drug, there will
be at least a sub-population of cells in a tumor which could
circumvent such a block by using an alternative signaling route. If the
whole network is involved, a precisely formulated combination
therapy will be required to fight the tumor growth effectively.
Moreover, such combination therapies might have to be specific for a
small subpopulation of patients or even individual patients given
patient-specific properties of oncogenic networks.
Dynamic nature of cellular responses and integration of
data generated by different technologies
In this study, concurrent measurements of gene expression and
protein levels following the treatment with synthetic androgen were
performed, and hundreds of genes and dozens of proteins whose
levels increased following the stimulus were indentified. However,
there isonlymodest overlap (about 17%) observed between the sets of
up-regulated genes and proteins. While initially this sounds
surprising, this result should be expected. Cells are complex dynamic
systems in which processes occur on multiple time scales. When we
assay a biological sample we are taking a static snapshot of this
dynamic behavior. For example levels of mRNA may increase after
20–60 min following the treatment but the protein synthesis could be
further delayed, and statistically significant change in protein
concentrations will take much longer to develop and have smaller
ratios. By the time proteins are synthesized some mRNA could be
degraded, leaving no trace of gene over-expression. Thus, when
studying microarray or proteomic data, we are dealing with
fragmented traces of activity that are left behind by transient
dynamic processes on different levels of cellular machinery. Even in
the experiments where samples are assayed at several different time-
points we are still looking at a small collection of individual snapshots
rather than the full picture of cellular dynamics.
Here we used the concept of topological significance to
reconstruct upstream pathways that might have resulted in these
traces of dynamic activity which we detected as observable
molecular profiles. The results indicate that this approach was
successful in predicting key regulatory proteins and pathways such
as androgen signaling, growth factor signaling and regulation of
cell cycle that mediate responses of LNCap cells to treatment with
synthetic androgen (R1881). Most importantly, we have discov-
ered that the degree of overlap between sets of regulatory proteins
predicted from gene expression and proteomic data is much
higher than the overlap between the experimental sets themselves
(52% vs. 17%). Moreover, for the growth factor regulation of the
cell cycle which appears to be a key process in this system, the
overlap reaches 76%. This provides a good indication that
predictions converge on the same set of regulatory proteins despite
significant paucity in the experimental data. Taken together, these
observations show that our approach could be instrumental in
translating high-throughput datasets generated by vastly different
technologies into consistent predictions of activity of underlying
signaling pathways and key regulatory proteins.
Methods
Cell culture and androgen treatment
Detailed procedures of cell culture and androgen treatment are
described in the recent PLoS publication [25]. Briefly, LNCaP
(ATCC number: CRL-1740
TM) cells were grown in RPMI 1640
medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum under 5% CO2 and 90% humidity. At 70%
confluence, the cells were subjected to androgen deprivation in
phenol red-free RPMI 1640 medium supplemented with charcoal-
stripped fetal bovine serum. After two days, androgen (R1881) was
added at 1 nm final concentration for 48 hrs. The control cells
were treated with corresponding amount of ethanol used to
dissolve androgen.
RNA Isolation and Microarray Analysis
Total RNA isolation was performed using TRIZOL reagent as per
the manufacturer’s instructions (Invitrogen) [25]. Control and
androgen treated cells were washed with PBS (phosphate buffered
saline) and scraped in TRIZOL reagent. 250 ml of chloroform was
added to 1 ml of sample and mixed by inversion. The sample was
centrifuged at 13,000 rpm for 15 min at 4uC. 500 mlo fi s o p r o p y l
alcohol was added to supernatant and centrifuged at 13,000 rpm for
15 min at 4uC. The resulting pellet was washed with 70% ethanol,
and centrifuged at 13,000 rpm for 10 minutes at 4uC. The RNA
pellet was dried and purified using RNeasy mini kit (QIAGEN Inc.,
Valencia, CA). The amount and integrity of purified RNA was
checked by NanoDrop ND-1000 Spectrophotometer (NanoDrop
Technologies, Wilmington, DE) and Agilent Bioanalyzer (Agilent
Technologies). RNAs isolated from three biological replicates were
used for microarray analysis performed on Affymetrix U133 Plus 2.0
arrays (Affymetrix, Inc., Santa Clara, CA). Complementary DNA
synthesis, cRNA synthesis, hybridization, washing, and scanning
were done following the manufacturer’s protocols (Affymetrix, Inc.).
Expression values were calculated after normalization of the data
based on previously published procedure [32]. Statistical Q test was
done to calculate falsediscovery rate (FDR), a FDR#1% was applied
to identify androgen-regulated genes. The data is publicly available at
GEO public repository website (accession number is GSE17044). All
data is MIAME compliant as detailed on the MGED Society website.
Proteomic analysis
Details of the iTRAQ- mass spectrometry and data analysis are
described in detail in [25]. Briefly, a double duplex iTRAQ
experiment was performed using the four-plex iTRAQ reagent
(iTRAQH Reagents Multiplex Kit, Applied Biosystems, Foster
City, CA). Proteins from duplicate sets of androgen-treated and
control cells were isolated using urea-thiourea containing buffer
and equal amounts of proteins were used for labeling by iTRAQ
reagents as per the manufacturer instructions (Applied Biosys-
tems). After labeling, all four samples were combined, and
subjected to two-dimensional fractionation by strong cation
exchange (SCX) and reverse phase liquid chromatography (RP-
LC). The RP-LC fractions were directly plated onto MALDI
plates online by infusing with the MALDI matrix alpha-cyano-4-
hydroxycinnamic acid. Tandem mass spectrometric data were
Networks in Prostate Cancer
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(Applied Biosystems) linked to 4000 Series Explorer software (v.
3.0). MS/MS spectra were extracted from the raw data in Mascot
Generic File format and converted to mzXML using IP
Framework (www.proteomecommons.org) for SEQUEST search
against Human IPI database version 3.24 appended with an equal
number of decoy sequences. In total, 8580 SEQUEST search
results (all from singly-charged spectra) were obtained and further
processed using PeptideProphet and ProteinProphet, leading to
the identification of 3686 peptides mapping to 904 proteins. Of
these, 3550 peptides were quantified with post-data normalization,
which mapped to 875 proteins. The estimated FDR using target-
decoy strategy was below 0.5%. After a median centered
normalization of peak areas of peptides, relative protein expression
(treated vs. control) ratios were determined for each protein. A
threshold ratio for defining differentially expressed proteins was set
based on control replicate sample; proteins with iTRAQ ratios of
.=1.2 and ,=0.83 were considered up-regulated and down-
regulated, respectively.
Algorithm for topological scoring of regulatory proteins
The identification of key regulatory proteins was performed using
freely available online tool provided by GeneGo Inc. (http://topology.
genego.com/zcgi/topology_scoring.cgi). The algorithm starts with a
set of differentially expressed genes or proteins derived from biological
samples. Typically these genes or proteins are identified by the
Figure 4. ‘‘Hidden’’ regulatory proteins in signaling pathways. (A) FGFR3 and p90RSK2 in this simple network are not affected on the gene
expression level, therefore remaining ‘‘hidden’’ from a microarray assay. We identify sets of remote targets associated with each of the signaling
molecules and assess their enrichment with differentially expressed genes. Remote targets of FGFR3 and p90RSK2 are proteins within the blue box.
They could be many steps downstream of signaling proteins. Topological significance is assigned to regulatory nodes based on the enrichment of
associated sets of target genes. Red boxes indicate topologically significant nodes in this network. (B) Topological scoring of regulatory nodes in
complex networks with competitive regulation. (See text for details).
doi:10.1371/journal.pone.0010936.g004
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experimental high-throughput techniques. We map such sets of genes
or proteins onto a global database of protein-protein interactions. The
online tool used in this study utilizes GeneGo’s MetaBase
TM
knowledgebase containing approximately 300,000 protein-protein
and protein-small molecule interactions manually extracted from the
literature by expert annotators. The simplified concept of topological
scoring is illustrated in Fig. 4a. This figure shows a signaling cascade
leading from FGFR3 receptor to a handful of target genes
downstream of transcription factor ATF-4. Gene expression data
from the present study are mapped onto this network. Up-regulated
genes are indicated by red circles associated with gene symbols. While
ATF-4 itself is over-expressed, neither the receptor nor the kinase
p90RSK2 which mediates signaling are up-regulated on genomic
level. To identify whether or not signaling proteins occupy
topologically significant positions with respect to up-regulated genes,
we consider network dependency graphs for each of them. Tracing
these graphs downstream to target genes allows us to associate a subset
of downstream targets with each of the signaling molecules. On Fig. 4a
the target genes in the blue box on the right can be associated with
FGFR3 and p90RSK2 as their ‘‘remote targets’’, while for ATF-4
they are direct targets. The final step is to calculate enrichment of
target gene-sets (remote or direct) associated with each regulatory
node with experimental data and determine the statistical significance
of such enrichment. A set of targets enriched in differentially expressed
genes would imply activity of corresponding regulator(s). In our
example, 10 out of 36 target genes are over-expressed, rendering
FGFR3, p90RSK2 and ATF-4 topologically significant. To summa-
rize, the general concept is to use topological properties of the global
protein interaction network to identify non-local regulation patterns
and associate a set of putative targets with each signaling molecule of
interest, then assess expression profiles of these targets and infer
activity of corresponding regulators. Given the role of network
topology in this assessment, we have named this procedure
‘‘topological significance scoring’’.
One caveat regarding the example above is that in real protein
interaction networks the picture is more complicated than simple
tree-like structures like the one shown on Fig. 4a. Most likely one has
to deal with a highly interconnected web of interactions where many
competitive cascades can regulate the same target. Additionally,
dependency graphs for many important signaling proteins are huge,
containing thousands of potential targets. For example, the full
dependency graph of p90RSK2 contains 49 potential ‘‘remote
targets’’ many of which can also be regulated by competitive
pathways. Our algorithm overcomes these issues by considering
overlaps of dependency graphs originating from different regulatory
nodes,thus taking into account competitiveregulation of target genes.
The idea isillustrated in Fig. 4b which shows an extended fragment of
dependency graph of p90RSK2. In addition to target genes regulated
viaATF-4 this networkcontains signaling via transcription factor YB-
1. None of the additional target genes is up-regulated in our dataset.
This significantly reduces the overall enrichment of the whole set of
remote targets of p90RSK2. The solution is to find a subset of targets
within the dependency graph of p90RSK2 that are fairly‘‘specific’’ to
this kinase, so that the pattern of their expression bears more
relevance to its activation status. To this end we consider alternative
regulators to which some of the downstream nodes could be
attributed. In this example we identify node in this graph are at least
as close or closer to the competitive regulator AKT1 as they are to
p90RSK2. The proximity can be calculated either using simple
network distance metrics (number of steps) or taking into account
additional information such as trust levels of interactions and
knowledge on well established ‘‘canonical’’ pathways. The nodes
that are at least as close to AKT1 are excluded from consideration
and enrichment is calculated for the remaining part of the
dependency graph (At this point the problem is reduced to the
analysis of gene set enrichment and any of the existing methods can
be applied [33],[34],[35]. In our technique this procedure is repeated
for multiple competitive regulators. We select the best score to
characterize protein of interest (p90RSK2 in this example).
Supporting Information
Table S1 The list of up- and down regulated genes and proteins.
We have performed concurrent measurements of gene expression
and protein levels following the treatment of LNCaP prostate
cancer cells with synthetic androgen. Using statistical analysis of
gene expression data we have identified 347 and 257 genes that
were up- and down-regulated, respectively, in treated vs. untreated
cells (FDR,1%). Using iTRAQ 2DLC-MS/MS-based proteomic
profiling of androgen-treated vs. untreated LNCap cells, we have
identified 70 and 39 proteins that were elevated or down-
regulated, respectively, in treated cells compared to untreated cells.
Found at: doi:10.1371/journal.pone.0010936.s001 (0.23 MB
PDF)
Table S2 List of topologically significant genes and proteins
determined from gene expression and proteomics data. The list of
up-regulated genes and proteins were submitted to the scoring
procedure separately, resulting in two sets of topologically
significant regulatory proteins. We identified 962 topologically
significant proteins from gene expression data and 577 topolog-
ically significant proteins from proteomic data (FDR,5%).
Found at: doi:10.1371/journal.pone.0010936.s002 (0.52 MB
PDF)
Table S3 Enrichment analysis of up-regulated genes and
proteins. The list of pathway maps and GeneGo process networks
significantly enriched in up-regulated genes and proteins. An FDR
threshold of 0.05 was used for maps and 0.2 for networks.
Found at: doi:10.1371/journal.pone.0010936.s003 (0.07 MB
PDF)
Table S4 Enrichment analysis of randomly extended up-
regulated genes and proteins. In order to investigate whether
significant differences in sizes of the sets used in our analysis could
have affected the results we randomly sampled the pool of genes
and proteins and added them to the differentially expressed sets.
Found at: doi:10.1371/journal.pone.0010936.s004 (0.07 MB
PDF)
Table S5 List of topologically significant genes and proteins
determined from truncated sets of up-regulated genes and proteins.
We removed the direct targets of androgen receptor from the list of
up-regulated genes and proteins. Direct targets were determined as
those proteins to which androgen receptor has a direct ‘‘transcription
regulation’’ type of interaction. The resulting truncated sets were re-
analyzed with the topological significance tool and 565 significant
proteins and 668 significant genes identified (FDR,5%).
Found at: doi:10.1371/journal.pone.0010936.s005 (0.43 MB
PDF)
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